SI1461359T1 - Nova anti IGF-IR protitelesa in njihova uporaba - Google Patents

Nova anti IGF-IR protitelesa in njihova uporaba

Info

Publication number: SI1461359T1
Authority: SI; Slovenia
Prior art keywords: igf; sequences; receptor; optionally; growth factor
Prior art date: 2002-01-18

Application number

SI200330732T

Other languages

English (en)

Inventor

Liliane Goetsch

Nathalie Corvaia

Olivier Leger

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-18

Filing date

2003-01-20

Publication date

2007-06-30

2002-01-18 Priority claimed from FR0200654A external-priority patent/FR2834900B1/fr

2002-01-18 Priority claimed from FR0200653A external-priority patent/FR2834990A1/fr

2002-05-07 Priority claimed from FR0205753A external-priority patent/FR2834991B1/fr

2003-01-20 Application filed by Pf Medicament filed Critical Pf Medicament

2007-06-30 Publication of SI1461359T1 publication Critical patent/SI1461359T1/sl

Links

101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 abstract 7
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 7
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 5
102000013275 Somatomedins Human genes 0.000 abstract 5
239000012634 fragment Substances 0.000 abstract 4
108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
102000001301 EGF receptor Human genes 0.000 abstract 2
108060006698 EGF receptor Proteins 0.000 abstract 2
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 2
241001529936 Murinae Species 0.000 abstract 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
101150029707 ERBB2 gene Proteins 0.000 abstract 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
241000699660 Mus musculus Species 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000002682 anti-psoriatic effect Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
210000004408 hybridoma Anatomy 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000011234 negative regulation of signal transduction Effects 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
238000011580 nude mouse model Methods 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
229960001603 tamoxifen Drugs 0.000 abstract 1
230000009261 transgenic effect Effects 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1
230000009452 underexpressoin Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biophysics (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SI200330732T 2002-01-18 2003-01-20 Nova anti IGF-IR protitelesa in njihova uporaba SI1461359T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
FR0200654A FR2834900B1 (fr)	2002-01-18	2002-01-18	Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
FR0200653A FR2834990A1 (fr)	2002-01-18	2002-01-18	Nouveaux anticorps anti-igf-ir et leurs applications
FR0205753A FR2834991B1 (fr)	2002-01-18	2002-05-07	Nouveaux anticorps anti-igf-ir et leurs applications
PCT/FR2003/000178 WO2003059951A2 (fr)	2002-01-18	2003-01-20	Anticorps anti-igf-ir et leurs applications
EP03712270A EP1461359B1 (fr)	2002-01-18	2003-01-20	Anticorps anti-igf-ir et leurs applications

Publications (1)

Publication Number	Publication Date
SI1461359T1 true SI1461359T1 (sl)	2007-06-30

Family

ID=27248849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200330732T SI1461359T1 (sl)	2002-01-18	2003-01-20	Nova anti IGF-IR protitelesa in njihova uporaba

Country Status (16)

Country	Link
EP (3)	EP1806364B1 (sl)
JP (2)	JP4606739B2 (sl)
CN (1)	CN100410275C (sl)
AT (1)	ATE357460T1 (sl)
AU (2)	AU2003216748B2 (sl)
BR (1)	BRPI0306973B8 (sl)
CA (1)	CA2473039C (sl)
CY (1)	CY1106662T1 (sl)
DE (1)	DE60312639T2 (sl)
DK (1)	DK1461359T3 (sl)
ES (2)	ES2283759T3 (sl)
MX (1)	MXPA04006980A (sl)
PT (1)	PT1461359E (sl)
SI (1)	SI1461359T1 (sl)
WO (1)	WO2003059951A2 (sl)
ZA (1)	ZA200405402B (sl)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10201182A1 (de)	2002-01-14	2003-07-24	Cfs Gmbh Kempten	Positioniersystem
US7553485B2 (en)	2002-01-18	2009-06-30	Pierre Fabre Medicament	Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
EP2316922B1 (en)	2002-05-24	2013-05-22	Merck Sharp & Dohme Corp.	Neutralizing human anti-IGFR antibody
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
US8034904B2 (en)	2002-06-14	2011-10-11	Immunogen Inc.	Anti-IGF-I receptor antibody
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
JP4473257B2 (ja)	2003-04-02	2010-06-02	エフ．ホフマン−ラロシュアーゲー	インスリン様成長因子ｉ受容体に対する抗体及びその使用
US7638605B2 (en)	2003-05-01	2009-12-29	ImClone, LLC	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) *	2003-07-10	2005-11-23	Hoffmann La Roche	Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN1835975B (zh)	2003-08-13	2012-11-21	辉瑞产品公司	经修饰的人类igf-1r抗体
CN1938428A (zh)	2003-11-12	2007-03-28	先灵公司	多基因表达的质粒系统
TW200526684A (en)	2003-11-21	2005-08-16	Schering Corp	Anti-IGFR1 antibody therapeutic combinations
WO2005058967A2 (en) *	2003-12-16	2005-06-30	Pierre Fabre Medicament	Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
CA2561686C (en) *	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
BRPI0513200A (pt)	2004-07-16	2008-04-29	Pfizer Prod Inc	uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
FR2873699B1 (fr) *	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
AU2011236042B2 (en) *	2004-07-29	2013-09-05	Pierre Fabre Medicament	Novel anti-IGF-IR antibodies and uses thereof
ES2356830T3 (es) *	2004-12-03	2011-04-13	Schering Corporation	Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
BRPI0608777A2 (pt) *	2005-04-15	2010-01-26	Schering Corp	métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas
PT2100614E (pt)	2005-06-17	2013-12-16	Imclone Llc	Antagonistas de receptor para tratamento de cancro ósseo metastático
WO2007000328A1 (en) *	2005-06-27	2007-01-04	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) *	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
EA017812B1 (ru) *	2005-12-08	2013-03-29	Медарекс, Инк.	Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
WO2007092453A2 (en)	2006-02-03	2007-08-16	Imclone Systems Incorporated	Igf-ir antagonists as adjuvants for treatment of prostate cancer
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2007093008A1 (en) *	2006-02-17	2007-08-23	Adelaide Research & Innovation Pty Ltd	Antibodies to insulin-like growth factor i receptor
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
EP2027470B1 (en) *	2006-06-02	2012-11-21	Pfizer Products Inc.	Circulating tumor cell assay
ES2427924T3 (es)	2006-06-30	2013-11-04	Merck Sharp & Dohme Corp.	Biomarcador IGFBP2
FR2906533B1 (fr)	2006-09-28	2013-02-22	Pf Medicament	Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
MX2009005400A (es) *	2006-11-29	2009-06-05	Genentech Inc	Metodo para el diagnostico y tratamiento del glioma.
US20110262525A1 (en)	2006-12-13	2011-10-27	Schering Corporation	Methods of treatment
GEP20115337B (en)	2007-01-10	2011-11-25	St Di Ricerche Di Biologia Molecolare P Angeletti Spa	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8492328B2 (en)	2007-05-17	2013-07-23	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2010528583A (ja) *	2007-06-11	2010-08-26	エーシーイミューンソシエテアノニム	アミロイドβに対するヒト化抗体
SG182192A1 (en) *	2007-06-12	2012-07-30	Ac Immune Sa	Humanized antibodies to amyloid beta
PE20090368A1 (es)	2007-06-19	2009-04-28	Boehringer Ingelheim Int	Anticuerpos anti-igf
AU2008282863A1 (en) *	2007-07-31	2009-02-05	Merck Sharp & Dohme Corp.	IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CA2701032C (en)	2007-09-27	2021-01-26	Amgen Inc.	Pharmaceutical formulations
EP3381445B1 (en)	2007-11-15	2023-10-25	Amgen Inc.	Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CN102164960A (zh) *	2008-09-26	2011-08-24	罗氏格黎卡特股份公司	双特异性抗-egfr/抗-igf-1r抗体
CN103396487A (zh)	2008-12-12	2013-11-20	贝林格尔.英格海姆国际有限公司	抗igf抗体
AR075982A1 (es)	2009-03-31	2011-05-11	Roche Glycart Ag	Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
US8470297B1 (en)	2009-09-10	2013-06-25	Merck Sharp & Dohme Corp.	FDG-pet evaluation of Ewing's sarcoma sensitivity
AU2010310457B2 (en)	2009-10-23	2015-07-02	Amgen Inc.	Vial adapter and system
HUE033758T2 (en)	2009-10-26	2017-12-28	Hoffmann La Roche	A method for producing glycosylated immunoglobulin
WO2011053779A2 (en)	2009-10-30	2011-05-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
EP2507392A4 (en)	2009-11-30	2013-06-05	Merck Sharp & Dohme	METHOD OF IDENTIFYING AND TREATING PATIENTS SENSITIVE TO ANTI-IGF-1R INHIBITION THERAPY
WO2011083391A2 (en)	2010-01-05	2011-07-14	Pfizer Inc.	Biomarkers for anti-igf-ir cancer therapy
KR102513760B1 (ko)	2010-06-07	2023-03-27	암젠 인크	약물 전달 장치
AU2011268934B2 (en)	2010-06-25	2015-09-10	Nykode Therapeutics ASA	Homodimeric protein constructs
CA2825894C (en)	2011-02-02	2021-11-30	Amgen Inc.	Prognosis of cancer using a circulating biomarker
EP2691065B1 (en)	2011-03-31	2017-03-01	Amgen Inc.	Vial adapter and system
CA2833748C (en)	2011-04-20	2019-07-16	Amgen Inc.	Autoinjector apparatus
WO2013056069A1 (en)	2011-10-13	2013-04-18	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP3335747B1 (en)	2011-10-14	2021-04-07	Amgen Inc.	Injector and method of assembly
US9700619B2 (en)	2011-11-11	2017-07-11	Duke University	Combination drug therapy for the treatment of solid tumors
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
CN102793922A (zh) *	2012-08-14	2012-11-28	四川汇宇制药有限公司	一种治疗哺乳动物体内肿瘤疾病的方法
EP3072548B1 (en)	2012-11-21	2019-03-06	Amgen, Inc	Drug delivery device
US20140255413A1 (en)	2013-03-07	2014-09-11	Boehringer Ingelheim International Gmbh	Combination therapy for neoplasia treatment
JP6336564B2 (ja)	2013-03-15	2018-06-06	アムゲン・インコーポレーテッド	薬物カセット、自動注入器、および自動注入器システム
CN111617347B (zh)	2013-03-15	2023-09-29	安进公司	身体轮廓可调适的自动注射器装置
US10492990B2 (en)	2013-03-15	2019-12-03	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
EP2976117B1 (en)	2013-03-22	2020-12-30	Amgen Inc.	Injector and method of assembly
CN103319598B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CN103319597B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	一种抗胰岛素样生长因子-1受体抗体及其编码基因和应用
JP6886816B2 (ja) *	2013-09-09	2021-06-16	カニムガイドセラピューティックスアーベー	免疫系調節薬
SG11201602876WA (en)	2013-10-24	2016-05-30	Amgen Inc	Injector and method of assembly
WO2015061389A1 (en)	2013-10-24	2015-04-30	Amgen Inc.	Drug delivery system with temperature-sensitive control
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
SG10201811702TA (en)	2014-05-07	2019-01-30	Amgen Inc	Autoinjector with shock reducing elements
MX387194B (es)	2014-06-03	2025-03-18	Amgen Inc	Sistemas y metodos para procesar de manera remota datos recolectados por un dispositivo de suministro de farmaco.
EP3943135B1 (en)	2014-10-14	2025-09-24	Amgen Inc.	Drug injection device with visual and audible indicators
US10799630B2 (en)	2014-12-19	2020-10-13	Amgen Inc.	Drug delivery device with proximity sensor
EP3689394A1 (en)	2014-12-19	2020-08-05	Amgen Inc.	Drug delivery device with live button or user interface field
ES2748750T3 (es)	2015-02-17	2020-03-17	Amgen Inc	Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
US11806509B2 (en)	2015-02-27	2023-11-07	Amgen Inc.	Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
ES2853582T3 (es)	2015-03-06	2021-09-16	Canimguide Therapeutics Ab	Moduladores del sistema inmune y composiciones
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
US11351308B2 (en)	2015-12-09	2022-06-07	Amgen Inc.	Auto-injector with signaling cap
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
CA3008437A1 (en)	2016-01-08	2017-07-13	Vaccibody As	Therapeutic anticancer neoepitope vaccine
EP3429663B1 (en)	2016-03-15	2020-07-15	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja)	2016-05-13	2023-07-18	アムジエン・インコーポレーテツド	バイアル・スリーブ組立体
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
WO2017209899A1 (en)	2016-06-03	2017-12-07	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
US11066396B2 (en)	2016-06-23	2021-07-20	Merck Sharp & Dohme Corp.	3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
EP3478342B1 (en)	2016-07-01	2025-03-12	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
MX2019008432A (es)	2017-01-17	2019-11-18	Amgen Inc	Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
MX2019009755A (es)	2017-02-17	2019-10-07	Amgen Inc	Mecanismo de insercion para dispositivo de suministro de farmacos.
US11752258B2 (en)	2017-02-17	2023-09-12	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018165143A1 (en)	2017-03-06	2018-09-13	Amgen Inc.	Drug delivery device with activation prevention feature
WO2018164829A1 (en)	2017-03-07	2018-09-13	Amgen Inc.	Needle insertion by overpressure
IL268386B2 (en)	2017-03-09	2023-11-01	Amgen Inc	Insertion mechanism for a drug delivery device
PL3600491T3 (pl)	2017-03-28	2024-03-04	Amgen Inc.	Układ i sposób montażu trzonu tłoka i strzykawki
EP3624820A1 (en) *	2017-04-21	2020-03-25	H. Hoffnabb-La Roche Ag	Use of klk5 antagonists for treatment of a disease
WO2018226515A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
EP3634546A1 (en)	2017-06-08	2020-04-15	Amgen Inc.	Torque driven drug delivery device
WO2018236619A1 (en)	2017-06-22	2018-12-27	Amgen Inc.	Device activation impact/shock reduction
JP7475860B2 (ja)	2017-06-23	2024-04-30	アムジエン・インコーポレーテツド	スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
EP3651832B1 (en)	2017-07-14	2023-12-13	Amgen Inc.	Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en)	2017-07-21	2023-06-13	Amgen Inc.	Gas permeable sealing member for drug container and methods of assembly
JP2020528296A (ja)	2017-07-25	2020-09-24	アムジエン・インコーポレーテツド	ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
JP7242562B2 (ja)	2017-07-25	2023-03-20	アムジエン・インコーポレーテツド	容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
US12318593B2 (en)	2017-08-09	2025-06-03	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en)	2017-08-18	2020-06-24	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
US11759565B2 (en)	2017-10-04	2023-09-19	Amgen Inc.	Flow adapter for drug delivery device
EP3691716B1 (en)	2017-10-06	2023-11-29	Amgen Inc.	Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en)	2017-10-09	2024-10-01	Amgen Inc	Drug delivery device with drive assembly and related assembly method
US11826480B2 (en)	2017-11-03	2023-11-28	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
MA50569A (fr)	2017-11-06	2020-09-16	Amgen Inc	Ensembles de remplissage-finition et procédés associés
MA50553A (fr)	2017-11-06	2020-09-16	Amgen Inc	Dispositif d'administration de médicament avec détection de positionnement et de débit
SG11202002966QA (en)	2017-11-10	2020-05-28	Amgen Inc	Plungers for drug delivery devices
JP7747438B2 (ja)	2017-11-16	2025-10-01	アムジエン・インコーポレーテツド	失速及び終点検出を有するオートインジェクタ
AU2018368340B2 (en)	2017-11-16	2024-03-07	Amgen Inc.	Door latch mechanism for drug delivery device
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
EP3826701A1 (en)	2018-07-24	2021-06-02	Amgen Inc.	Delivery devices for administering drugs
WO2020023220A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MX2021000749A (es)	2018-07-24	2021-03-29	Amgen Inc	Dispositivos de suministro para administrar farmacos.
WO2020028009A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en)	2018-08-02	2024-02-27	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en)	2018-08-02	2024-09-24	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en)	2018-08-02	2025-07-29	Dyne Therapeutics, Inc.	Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
JP2022500095A (ja)	2018-09-24	2022-01-04	アムジエン・インコーポレーテツド	インターベンション投薬システム及び方法
IL281469B2 (en)	2018-09-28	2024-08-01	Amgen Inc	Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en)	2018-10-02	2021-08-11	Amgen Inc.	Injection systems for drug delivery with internal force transmission
US12151089B2 (en)	2018-10-05	2024-11-26	Amgen Inc.	Drug delivery device having dose indicator
SG11202101824VA (en)	2018-10-15	2021-03-30	Amgen Inc	Platform assembly process for drug delivery device
MA53912A (fr)	2018-10-15	2022-01-19	Amgen Inc	Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
AU2019370159B2 (en)	2018-11-01	2025-05-29	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566B1 (en)	2018-11-01	2024-11-27	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
US20220160972A1 (en)	2019-04-24	2022-05-26	Amgen Inc.	Syringe sterilization verification assemblies and methods
JP7608439B2 (ja)	2019-08-23	2025-01-06	アムジエン・インコーポレーテツド	構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
EP4087878A4 (en) *	2020-01-10	2024-06-05	Dyne Therapeutics, Inc.	MUSCLE-TARGETED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
BR112022013686A2 (pt) *	2020-01-10	2022-09-06	Dyne Therapeutics Inc	Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia miotônica
US20240208680A1 (en)	2021-05-21	2024-06-27	Amgen Inc.	Method of optimizing a filling recipe for a drug container
US11633498B2 (en)	2021-07-09	2023-04-25	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20250004770A (ko)	2022-04-15	2025-01-08	다인 세라퓨틱스, 인크.	근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6267896A (en) *	1995-06-07	1996-12-30	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth oftumors
BR0110927A (pt) *	2000-05-19	2003-03-11	Scancell Ltd	Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
AR032028A1 (es) *	2001-01-05	2003-10-22	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina

2003
- 2003-01-20 DK DK03712270T patent/DK1461359T3/da active
- 2003-01-20 SI SI200330732T patent/SI1461359T1/sl unknown
- 2003-01-20 AU AU2003216748A patent/AU2003216748B2/en not_active Expired
- 2003-01-20 EP EP06126430.5A patent/EP1806364B1/fr not_active Expired - Lifetime
- 2003-01-20 MX MXPA04006980A patent/MXPA04006980A/es active IP Right Grant
- 2003-01-20 EP EP03712270A patent/EP1461359B1/fr not_active Expired - Lifetime
- 2003-01-20 CA CA2473039A patent/CA2473039C/fr not_active Expired - Lifetime
- 2003-01-20 DE DE60312639T patent/DE60312639T2/de not_active Expired - Lifetime
- 2003-01-20 AT AT03712270T patent/ATE357460T1/de active
- 2003-01-20 WO PCT/FR2003/000178 patent/WO2003059951A2/fr not_active Ceased
- 2003-01-20 BR BRPI0306973A patent/BRPI0306973B8/pt not_active IP Right Cessation
- 2003-01-20 ES ES03712270T patent/ES2283759T3/es not_active Expired - Lifetime
- 2003-01-20 ES ES06126430T patent/ES2427964T3/es not_active Expired - Lifetime
- 2003-01-20 CN CNB038024489A patent/CN100410275C/zh not_active Expired - Lifetime
- 2003-01-20 PT PT03712270T patent/PT1461359E/pt unknown
- 2003-01-20 JP JP2003560053A patent/JP4606739B2/ja not_active Expired - Lifetime
- 2003-01-20 EP EP06126429A patent/EP1798242B1/fr not_active Expired - Lifetime
2004
- 2004-07-07 ZA ZA2004/05402A patent/ZA200405402B/en unknown
2007
- 2007-06-15 CY CY20071100801T patent/CY1106662T1/el unknown
2009
- 2009-04-24 AU AU2009201674A patent/AU2009201674B2/en not_active Expired
2010
- 2010-05-31 JP JP2010124341A patent/JP2010233575A/ja active Pending

Also Published As

Publication number	Publication date
EP1806364A3 (fr)	2010-09-08
PT1461359E (pt)	2007-06-29
JP2010233575A (ja)	2010-10-21
AU2003216748B2 (en)	2009-07-16
ATE357460T1 (de)	2007-04-15
CA2473039A1 (fr)	2003-07-24
AU2003216748A1 (en)	2003-07-30
HK1078590A1 (zh)	2006-03-17
ES2283759T3 (es)	2007-11-01
DE60312639T2 (de)	2007-11-29
JP2005536181A (ja)	2005-12-02
WO2003059951A2 (fr)	2003-07-24
BRPI0306973B1 (pt)	2020-03-03
ES2427964T3 (es)	2013-11-05
AU2009201674A1 (en)	2009-05-21
EP1798242A2 (fr)	2007-06-20
DE60312639D1 (de)	2007-05-03
DK1461359T3 (da)	2007-07-09
BR0306973A (pt)	2004-11-09
EP1461359B1 (fr)	2007-03-21
JP4606739B2 (ja)	2011-01-05
WO2003059951A3 (fr)	2004-04-15
AU2009201674B2 (en)	2012-08-16
BRPI0306973B8 (pt)	2021-05-25
CA2473039C (fr)	2014-09-23
EP1806364A2 (fr)	2007-07-11
EP1798242A3 (fr)	2010-09-08
ZA200405402B (en)	2005-03-30
EP1461359A2 (fr)	2004-09-29
EP1798242B1 (fr)	2013-01-23
EP1806364B1 (fr)	2013-07-31
CN1620468A (zh)	2005-05-25
CN100410275C (zh)	2008-08-13
MXPA04006980A (es)	2004-11-10
WO2003059951A8 (fr)	2004-07-29
CY1106662T1 (el)	2012-05-23

Publication	Publication Date	Title
SI1461359T1 (sl)	2007-06-30	Nova anti IGF-IR protitelesa in njihova uporaba
RU2406729C2 (ru)	2010-12-20	Новые анти-igf-ir и их применение
RU2434882C2 (ru)	2011-11-27	Новые антитела к igf-ir и их применение
Geiser et al.	1991	Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene
Nikiforov	2002	RET/PTC rearrangement in thyroid tumors
AR039067A1 (es)	2005-02-09	Anticuerpos para cd40
UA74330C2 (uk)	2005-12-15	СПОСОБИ ВИКОРИСТАННЯ РОЗЧИННОГО РЕЦЕПТОРА BR43x2
TW200817435A (en)	2008-04-16	Compositions and methods for modulating vascular development
UA87804C2 (ru)	2009-08-25	Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
JPWO2019224718A5 (sl)	2022-06-20
CN116178547A (zh)	2023-05-30	Cd3抗原结合片段及其应用
Robb et al.	1997	The SCL/TAL1 gene: roles in normal and malignant haematopoiesis
EP0150572A1 (en)	1985-08-07	Microbial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides
Armstrong et al.	1992	Expression of fibroblast growth factor receptors in human leukemia cells
Mincione et al.	2011	EGF and TGF‐β1 Effects on Thyroid Function
CN107502671B (zh)	2020-05-05	利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用
JPH05502789A (ja)	1993-05-20	ムチンヌクレオチド
CN108948201B (zh)	2019-05-07	抗人csf-1r单克隆抗体及应用
CA2584646A1 (en)	2006-06-01	Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
Nawachi et al.	2002	Tyrosine kinase-type receptor ErbB4 in chondrocytes: interaction with connective tissue growth factor and distribution in cartilage
CN109053887B (zh)	2019-07-23	一种抗人csf-1r单克隆抗体及用途
US7265260B2 (en)	2007-09-04	Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
CN101307302B (zh)	2012-02-29	分泌抗人天冬酰胺羟化酶单克隆抗体的杂交瘤细胞制备工艺
TWI730450B (zh)	2021-06-11	抗體，包含該抗體的套組，以及其用途
CN1165618C (zh)	2004-09-08	多核苷酸免疫原性剂